AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings

Thursday, May 30, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- AbbVie to present more than 40 abstracts from its oncology pipeline at this year's ASCO and EHA medical meetings in June

Abstract

Presentation Timing

ASCO Annual Meeting

Ibrutinib

Final Analysis From RESONATE: 6-Year Follow-upin Patients (Pts) With Previously Treated ChronicLymphocytic Leukemia or Small LymphocyticLymphoma (CLL/SLL) on Ibrutinib; Barr et al.; Abstract #7510

Monday, June 3

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 11:30 a.m. - 1:00 p.m. CT

Patient-Reported Outcomes (PROs) With Ibrutinib-Rituximab in WaldenströmMacroglobulinemia (WM): Results From iNNOVATE™; Tedeschi et al.; Abstract #8018

Monday, June 3

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 1:15 p.m. - 2:45 p.m. CT

Interim Analysis of Ibrutinib Plus Paclitaxel forPatients With Advanced Urothelial Carcinoma Previously Treated With Platinum-Based Chemotherapy; Castellano et al.; Abstract #4522

Monday, June 3

Poster Session: 1:15 p.m. - 4:15 p.m. CT

Venetoclax

Effect of Fixed-Duration Venetoclax PlusObinutuzumab (VenG) on Progression-Free Survival (PFS), and Rates and Duration of MinimalResidual Disease Negativity (MRD-) in PreviouslyUntreated Patients (pts) with ChronicLymphocytic Leukemia (CLL) and Comorbidities; Fischer K, et al.; Abstract #7502

Tuesday, June 4

Oral Session: 9:45 a.m. - 12:45 p.m. CT

Oral Presentation: 10:09 a.m. - 10:21 a.m. CT

Outcomes of Patients with t(11;14) MultipleMyeloma: An International Myeloma Working Group (IMWG) Multicenter Study; Durie BG, et al.; Abstract #8015

Monday, June 3

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 1:15 p.m. - 2:45 p.m. CT

Randomized Phase 2 Trial of Venetoclax +Fulvestrant Versus Fulvestrant in Estrogen Receptor+, HER2- Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression During or After a CDK4/6 Inhibitor: VERONICA; Lindeman GJ, et al.; Abstract #TPS1108

Sunday, June 2

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Veliparib

Veliparib in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation inPatients with Stage III Non-Small Cell Lung Cancer (NSCLC); Kozono DE, et al.; Abstract #8510

Sunday, June 2

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 11:15 a.m. - 12:45 p.m. CT

Mivebresib

Results from the First-in-Human Study of Mivebresib (ABBV-075), a Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Acute Myeloid Leukemia; Odenike O, et al.; Abstract #7030

Monday, June 3

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Cell Free DNA in Uveal Melanoma: Results from the First in Human Trial of Mivebresib (ABBV-075); Patel SP, et al.; Online Publication

Online Publication

Depatux-M

Phase 1/2 Study of Depatuxizumab Mafodotin (ABT-414) Monotherapy or Combination with Temozolomide in Japanese Patients with/without EGFR-Amplified Recurrent Glioblastoma; Narita Y,et al.; Abstract #2065

Sunday, June 2

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Rova-T

Phase 1 Study on Preliminary Efficacy of Rovalpituzumab Tesirine in Japanese Patients with Advanced, Recurrent Small Cell Lung Cancer; Akamatsu H, et al.; Abstract #8557

Sunday, June 2

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Ph1/2 Study of Rova-T in Combination with Nivolumab (Nivo) ± Ipilimumab (Ipi) for Patients (Pts) with 2L+ Extensive-Stage (ED) SCLC; Malhotra J, et al.; Abstract #8516

Sunday, June 2

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 11:15 a.m. - 12:45 p.m. CT

Predictors Associated with Development of Pleural and Pericardial Effusions in Patients with Small Cell Lung Cancer Treated with Third-Line Therapy; Jiang R, et al.; Online Publication

Online Publication

Teslio-V

Results of the Phase 1b Study of ABBV-399 (Telisotuzumab Vedotin; Teliso-V) in Combination with Erlotinib in Patients with c-Met+ Non-Small Cell Lung Cancer by EGFR Mutation Status; Camidge DR, et al.; Abstract #3011

Saturday, June 1

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 3:00 p.m. - 4:30 p.m. CT

c-Met Expression and Response to Telisotuzumab Vedotin (Teliso-V) in Patients with Non-Small Cell Lung Cancer; Heist RS, et al.; Abstract #9023

Sunday, June 2

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 4:30 p.m. - 6:00 p.m. CT

Peripheral Neuropathy Among Patients with NSCLC Undergoing Chemotherapy; Tyczynski JE, et al.; Online Publication

Online Publication

ABBV-085

First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug Conjugate (ADC) Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors; Demetri GD, et al.; Abstract #3004

Monday, June 3

Oral Session: 8:00 a.m. - 11:00 a.m. CT

Oral Presentation: 9:12 a.m. - 9:24 a.m. CT

ABBV-621

Phase 1, First-In-Human Study of TRAIL Receptor Agonist Fusion Protein ABBV-621; Ratain MJ, et al.; Abstract #3013

Saturday, June 1

Poster Session: 8:00 a.m. - 11:00 a.m. CT

Poster Discussion: 3:00 p.m. - 4:30 p.m. CT

ABBV-181

Safety and Efficacy of Anti-PD-1 Inhibitor ABBV-181 in Lung and Head and Neck Carcinoma; Italiano A, et al.; Online Publication

Online Publication

EHA Annual Congress 

Ibrutinib

Five Year Follow-Up of Patients Receiving Ibrutinib for First-Line Treatment of Chronic Lymphocytic Leukemia; Tedeschi A, et al.; Abstract #S107

Monday, June 14

Oral Session: 11:30 a.m. - 12:45 p.m. CEST

Oral Presentation: 12:00 p.m. - 12:15 p.m. CEST

Patient-Reported Outcomes from theiNNOVATETM Study: Results of Ibrutinib-Rituximab in Waldenström Macroglobulinemia (WM); Tedeschi A, et al.; Abstract #PF614

Monday, June 14

Poster Display: 5:30 p.m. - 7:00 p.m. CEST

Prognostic Testing and Treatment Approaches Based on Real-World Clinical Experience from an Interim Analysis of the INFORMCLL Registry ofPatients with Chronic Lymphocytic Leukemia; Mato AR, et al.; Abstract #PF383

Monday, June 14

Poster Display: 5:30 p.m. - 7:00 p.m. CEST

Venetoclax

A Phase 1b/2 Clinical Study of Targeted IDH1 Inhibition with Ivosidenib in Combination with the BCL-2 Inhibitor Venetoclax for Patients with IDH1-mutated (mIDH1) Myeloid Malignancies; DiNardo CD, et al.;  Abstract #PF291

Friday, June 14

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

 

Factors Impacting Treatment Selection in Treatment-Naïve Patients with CLL: A Multicenter Study; Rhodes J, et al.; Abstract #PF381

Friday, June 14

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

 

Venetoclax for Chronic Lymphocytic Leukemia: ARetrospective Chart Review of Safety and Efficacy From Preapproval Cohort Programs in the European Union; Schuh, et al.; Abstract #PS1165

Saturday, June 15

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

Venetoclax Alone or in Combination with Rituximab for Japanese Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia; Yamamoto K, et al.; Abstract #PB1890

Online Publication

Efficacy and Safety of Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia in Patients Previously Treated with Venetoclax in the MURANO Study; Greil R, et al.; Abstract #PS1161

Saturday, June 15

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

Impact of Major Genomic Alterations on Outcome of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated With Venetoclax Plus Rituximab (Venr) in the Phase 3 MURANO Study; Wu J, et al.; Abstract #PS1123

Saturday, June 15

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

Genetic Markers and Outcome in the CLL14 Trial of the GCLLSG Comparing Front Line Obinutuzumab Plus Chlorambucil or Venetoclax in Patients with Comorbidity; Tausch E, et al.; Abstract #S105

Friday, June 14

Oral Presentation: 11:30 a.m. - 11:45 a.m. CEST

Updated Safety and Efficacy From a Phase 2 Study of Venetoclax Plus Carfilzomib andDexamethasone in Patients with Relapsed/Refractory Multiple Myeloma; Costa LJ, et al.; Abstract #PS1375

Saturday, June 15

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

Improved Outcome in Patients With BCL2-Positive Diffuse Large B-Cell Lymphoma Treated With Venetoclax Plus R-Chop: Results From the Phase 2 CAVALLI Study; Morschhauser F, et al.; Abstract #PF294

Friday, June 14

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

 

Mivebresib

Results From the First-In-Human Study of Mivebresib (Abbv-075), a Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients With Relapsed/Refractory Acute MyeloidLeukemia; Borthakur G, et al.; Abstract #PF254

Friday, June 14

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

 

Navitoclax

Combination BCL-2 Inhibitor Therapy With Venetoclax (Ven) and Navitoclax (Nav) in Patientswith Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL); Pullarkat V, et al.; Abstract #PS940

Saturday, June 15

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

Additional Research

Outcomes Of Patients With t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study; Kumar S, et al.; Abstract #PF564

Friday, June 14

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

 

Longitudinal Treatment Patterns and Patient Characteristics Among Individuals DiagnosedWith CLL in Israel; Weil C, et al.; Abstract #PS1166

Saturday, June 15

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

Patient Characteristics, Transplant Frequency,and Treatments in Multiple Myeloma; Karve S, et al.; Abstract #PF724

Friday, June 14

Poster Session: 5:30 p.m. - 7:00 p.m. CEST

 



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store